|
CN103191101A
|
|
Composition containing dihydroartemisinin
|
|
CN103193652A
|
|
Method for preparing repaglinide intermediate
|
|
CN103169646A
|
|
Quinine sulfate compound
|
|
CN103169647A
|
|
Artemether compound
|
|
CN103169648A
|
|
Primaquine diphosphate compound
|
|
CN103191117A
|
|
Composition containing diethylcarbamazine citrate
|
|
CN103191438A
|
|
Composition containing sulfadoxine
|
|
CN103191084A
|
|
Composition containing bithionol
|
|
CN103191113A
|
|
Composition containing chloroquine phosphate
|
|
CN102731528A
|
|
Amoxicillin C crystal form
|
|
CN102731311A
|
|
Method for preparing 4-ethoxycarbonyl-3-ethoxybenzeneacetic acid
|
|
CN102731483A
|
|
Method for preparing 5-methoxyl-2-[[(4-methoxyl-3,5-dimethyl-2-pyridyl)-methyl]-sulfenyl]-1H-benzimidazole
|
|
CN102731480A
|
|
Pymeprazole crystal form E
|
|
CN102731481A
|
|
Pymeprazole crystal form D
|
|
CN102731482A
|
|
Pymeprazole crystal form B
|
